European Regulators Back Santhera's Expanded Muscular Dystrophy Treatment for Toddlers

Pratteln, Monday, 27 April 2026.
European regulators recommended expanding Santhera’s muscular dystrophy drug to children aged two and older. Notably, the therapy yields an 80% reduction in vertebral fractures compared to traditional treatments.